Emiliano Tamburini

机构：Cardinal Health (Australia), Ospedale di Cattinara, Ospedale Pediatrico Giovanni XXIII, Robotic Technology (United States), European Association for Palliative Care · ORCID：0000-0003-4619-7091

发表论文 276 篇 · 总被引 4976 次 · h-index 36

代表论文

• Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial (2025 · The Lancet · 被引 27)
• Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO (2025 · Annals of Oncology · 被引 17)
• Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study (2026 · Journal of Clinical Oncology · 被引 13)
• Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers (2025 · Liver International · 被引 11)
• Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial (2025 · Annals of Oncology · 被引 8)
• Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab (2025 · European Journal of Cancer · 被引 3)